Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Head & Neck 1

Conditions

Salivary Gland Neoplasms 1

Interventions

Cisplatin 89pembrolizumab 83Magnetic Resonance Spectroscopy 47Radiotherapy, Intensity-Modulated 41Specimen Handling 37Cetuximab 37Carboplatin 37Radiotherapy 36Nivolumab 29Paclitaxel 25Platinum 23Radiation 22Docetaxel 22Gemcitabine 21Biopsy 211,2-diaminocyclohexaneplatinum II citrate 21Surveys and Questionnaires 17Fluorouracil 14toripalimab 13Standard of Care 13Taxes 11Cyclophosphamide 10cemiplimab 9atezolizumab 9X-Rays 9Surgical Procedures, Operative 9Ipilimumab 9Immunoglobulin G 9Drug Therapy 9Capecitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
luprolide acetate gel depot × Head & Neck × 90 days × Clear all
NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡